Drugs / HPDSC
last change Jan 2022 re-read 2 minutes ago

HPDSC

Cell therapy

Developed for
brain hypoxia - ischemia
Investigated by
Celgene Corporation · New York Medical College

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02434965 Dec 2019 → Jan 2021 brain hypoxia - ischemia New York Medical College Withdrawn No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HPDSC ClinicalTrials.gov intervention name — accepted as the source's own label NCT02434965
Modality Cell therapy “human placental-derived stem cells (HPDSC)” NCT02434965
Route Intravenous intravenous administration of autologous cord blood (CB) and autologous human placental derived stem cells (HPDSC)” NCT02434965